 Daniel Pastula
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 9 | 2018 | 155 | 2.040 |
Why?
| | Encephalitis, California | 4 | 2019 | 11 | 1.780 |
Why?
| | Epilepsy | 7 | 2024 | 322 | 1.630 |
Why?
| | Guillain-Barre Syndrome | 5 | 2017 | 22 | 1.450 |
Why?
| | Encephalitis, Tick-Borne | 3 | 2023 | 8 | 1.360 |
Why?
| | Flavivirus Infections | 2 | 2019 | 9 | 1.310 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2015 | 68 | 1.300 |
Why?
| | Disease Outbreaks | 8 | 2023 | 349 | 1.290 |
Why?
| | Bunyaviridae Infections | 3 | 2019 | 8 | 1.240 |
Why?
| | Central Nervous System Diseases | 2 | 2023 | 69 | 1.230 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 196 | 1.230 |
Why?
| | Monkeypox virus | 3 | 2023 | 13 | 1.190 |
Why?
| | Nervous System Diseases | 4 | 2023 | 252 | 1.090 |
Why?
| | Chikungunya Fever | 2 | 2017 | 76 | 0.970 |
Why?
| | Meningitis | 2 | 2023 | 79 | 0.960 |
Why?
| | Encephalitis | 3 | 2023 | 131 | 0.940 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.840 |
Why?
| | Neurology | 3 | 2024 | 103 | 0.840 |
Why?
| | Arbovirus Infections | 2 | 2023 | 19 | 0.840 |
Why?
| | Smallpox Vaccine | 1 | 2023 | 23 | 0.830 |
Why?
| | Flavivirus | 2 | 2019 | 17 | 0.810 |
Why?
| | Optic Neuritis | 1 | 2023 | 40 | 0.800 |
Why?
| | Encephalomyelitis | 1 | 2022 | 9 | 0.800 |
Why?
| | Encephalitis Virus, California | 3 | 2019 | 6 | 0.780 |
Why?
| | Phlebovirus | 3 | 2020 | 4 | 0.770 |
Why?
| | Exanthema | 1 | 2022 | 74 | 0.760 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 107 | 0.740 |
Why?
| | Creatine | 2 | 2012 | 58 | 0.730 |
Why?
| | Neuroprotective Agents | 2 | 2012 | 121 | 0.690 |
Why?
| | Acyclovir | 1 | 2020 | 99 | 0.660 |
Why?
| | Encephalomyelitis, Eastern Equine | 1 | 2019 | 5 | 0.650 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 29 | 0.630 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 353 | 0.590 |
Why?
| | Thrombocytopenia | 2 | 2017 | 189 | 0.590 |
Why?
| | Hepatitis E | 1 | 2017 | 2 | 0.540 |
Why?
| | Hepatitis E virus | 1 | 2017 | 2 | 0.540 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 50 | 0.540 |
Why?
| | Myelitis | 4 | 2021 | 98 | 0.530 |
Why?
| | Communicable Diseases, Emerging | 1 | 2016 | 32 | 0.490 |
Why?
| | Dengue | 1 | 2016 | 69 | 0.490 |
Why?
| | Antiviral Agents | 1 | 2020 | 719 | 0.450 |
Why?
| | Humans | 51 | 2024 | 129847 | 0.450 |
Why?
| | Ixodidae | 1 | 2014 | 5 | 0.450 |
Why?
| | Zika Virus | 5 | 2018 | 118 | 0.420 |
Why?
| | Critical Care | 1 | 2017 | 552 | 0.390 |
Why?
| | Enterovirus Infections | 3 | 2021 | 171 | 0.360 |
Why?
| | Homosexuality, Male | 2 | 2022 | 176 | 0.360 |
Why?
| | Meningoencephalitis | 2 | 2021 | 25 | 0.350 |
Why?
| | Male | 25 | 2024 | 63759 | 0.290 |
Why?
| | United States | 11 | 2024 | 13913 | 0.290 |
Why?
| | Infant | 9 | 2022 | 9018 | 0.280 |
Why?
| | Muscle Hypotonia | 2 | 2018 | 31 | 0.280 |
Why?
| | Fatal Outcome | 4 | 2018 | 300 | 0.280 |
Why?
| | Population Surveillance | 4 | 2018 | 439 | 0.280 |
Why?
| | North America | 2 | 2019 | 294 | 0.270 |
Why?
| | Motor Neuron Disease | 3 | 2012 | 16 | 0.270 |
Why?
| | Child, Preschool | 8 | 2022 | 10522 | 0.260 |
Why?
| | Culicidae | 2 | 2016 | 31 | 0.240 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 82 | 0.230 |
Why?
| | Animals | 11 | 2023 | 35409 | 0.230 |
Why?
| | Infant, Newborn | 4 | 2022 | 5772 | 0.220 |
Why?
| | Child | 10 | 2022 | 20962 | 0.220 |
Why?
| | Rituximab | 2 | 2023 | 164 | 0.220 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2023 | 91 | 0.220 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 24 | 0.210 |
Why?
| | Middle Aged | 12 | 2024 | 31177 | 0.210 |
Why?
| | Adolescent | 11 | 2024 | 20451 | 0.210 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 50 | 0.200 |
Why?
| | District of Columbia | 1 | 2022 | 27 | 0.200 |
Why?
| | Encephalitis, Viral | 1 | 2023 | 43 | 0.200 |
Why?
| | West Nile Fever | 1 | 2023 | 51 | 0.200 |
Why?
| | Registries | 1 | 2009 | 1903 | 0.190 |
Why?
| | Enterovirus A, Human | 1 | 2021 | 12 | 0.180 |
Why?
| | Adult | 12 | 2024 | 35634 | 0.180 |
Why?
| | Young Adult | 7 | 2024 | 12467 | 0.180 |
Why?
| | Age of Onset | 2 | 2015 | 494 | 0.180 |
Why?
| | Acute Disease | 4 | 2018 | 980 | 0.180 |
Why?
| | Health Surveys | 2 | 2024 | 495 | 0.180 |
Why?
| | Education, Medical | 1 | 2024 | 254 | 0.170 |
Why?
| | Vital Capacity | 2 | 2012 | 290 | 0.170 |
Why?
| | Colorado | 3 | 2022 | 4410 | 0.170 |
Why?
| | Hashimoto Disease | 1 | 2020 | 11 | 0.170 |
Why?
| | Disease Progression | 4 | 2012 | 2628 | 0.170 |
Why?
| | Simplexvirus | 1 | 2020 | 80 | 0.170 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 73 | 0.170 |
Why?
| | Incidence | 5 | 2018 | 2646 | 0.170 |
Why?
| | Interferon-gamma | 1 | 2023 | 773 | 0.160 |
Why?
| | Bunyamwera virus | 1 | 2019 | 3 | 0.160 |
Why?
| | Comorbidity | 1 | 2024 | 1551 | 0.160 |
Why?
| | Administration, Intravenous | 1 | 2020 | 142 | 0.160 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 105 | 0.160 |
Why?
| | Aged | 10 | 2024 | 22107 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2021 | 229 | 0.160 |
Why?
| | Stem Cells | 1 | 2023 | 578 | 0.150 |
Why?
| | Central Nervous System Infections | 1 | 2019 | 35 | 0.150 |
Why?
| | Immunoglobulin G | 1 | 2023 | 851 | 0.150 |
Why?
| | Seizures | 1 | 2022 | 402 | 0.150 |
Why?
| | Autopsy | 2 | 2015 | 92 | 0.150 |
Why?
| | Veterans | 1 | 2009 | 1383 | 0.140 |
Why?
| | La Crosse virus | 1 | 2017 | 6 | 0.140 |
Why?
| | Motor Disorders | 1 | 2018 | 15 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3397 | 0.140 |
Why?
| | Skin | 1 | 2022 | 725 | 0.140 |
Why?
| | Fever | 2 | 2017 | 298 | 0.140 |
Why?
| | Micronesia | 1 | 2017 | 3 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2012 | 1368 | 0.140 |
Why?
| | Female | 16 | 2024 | 68829 | 0.140 |
Why?
| | Encephalomyelitis, Equine | 1 | 2016 | 1 | 0.140 |
Why?
| | Pandemics | 2 | 2023 | 1500 | 0.140 |
Why?
| | Encephalitis Virus, Eastern Equine | 1 | 2016 | 2 | 0.140 |
Why?
| | International Classification of Diseases | 1 | 2017 | 122 | 0.130 |
Why?
| | Fiji | 1 | 2016 | 3 | 0.130 |
Why?
| | Diagnostic Errors | 1 | 2017 | 162 | 0.130 |
Why?
| | Arthropod Vectors | 1 | 2016 | 7 | 0.130 |
Why?
| | Neurologic Examination | 1 | 2016 | 114 | 0.130 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2016 | 8 | 0.130 |
Why?
| | Ticks | 1 | 2016 | 20 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 602 | 0.120 |
Why?
| | Aged, 80 and over | 3 | 2017 | 7066 | 0.120 |
Why?
| | Thogotovirus | 1 | 2015 | 1 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1937 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 263 | 0.120 |
Why?
| | Lyme Disease | 1 | 2015 | 57 | 0.120 |
Why?
| | Chikungunya virus | 1 | 2016 | 76 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2018 | 367 | 0.110 |
Why?
| | Plant Oils | 1 | 2013 | 29 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2014 | 483 | 0.100 |
Why?
| | Quality of Life | 2 | 2022 | 2695 | 0.100 |
Why?
| | Models, Statistical | 1 | 2017 | 624 | 0.100 |
Why?
| | Puerto Rico | 3 | 2017 | 52 | 0.100 |
Why?
| | Linear Models | 1 | 2015 | 822 | 0.100 |
Why?
| | Curriculum | 1 | 2019 | 928 | 0.100 |
Why?
| | Age Factors | 2 | 2018 | 3161 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2016 | 3384 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1089 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1920 | 0.090 |
Why?
| | Health Promotion | 1 | 2017 | 718 | 0.090 |
Why?
| | Hospitalization | 2 | 2017 | 2079 | 0.090 |
Why?
| | Multiple Sclerosis | 1 | 2015 | 438 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2015 | 462 | 0.080 |
Why?
| | Vietnam | 1 | 2009 | 26 | 0.080 |
Why?
| | Alzheimer Disease | 1 | 2015 | 516 | 0.080 |
Why?
| | Muscle Cramp | 1 | 2009 | 7 | 0.080 |
Why?
| | Piracetam | 1 | 2009 | 13 | 0.080 |
Why?
| | Influenza, Human | 1 | 2015 | 602 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 532 | 0.080 |
Why?
| | Muscle Spasticity | 1 | 2009 | 55 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2009 | 209 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 851 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1199 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2009 | 628 | 0.060 |
Why?
| | Prevalence | 2 | 2024 | 2564 | 0.060 |
Why?
| | Survival Rate | 1 | 2009 | 1872 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2677 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1005 | 0.050 |
Why?
| | Astrocytes | 1 | 2023 | 197 | 0.050 |
Why?
| | Eosinophils | 1 | 2023 | 324 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 133 | 0.040 |
Why?
| | Microspheres | 1 | 2020 | 131 | 0.040 |
Why?
| | Immunoassay | 1 | 2020 | 108 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2020 | 179 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 477 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 276 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1724 | 0.040 |
Why?
| | Missouri | 1 | 2018 | 69 | 0.040 |
Why?
| | Epilepsia Partialis Continua | 1 | 2017 | 4 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 816 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 181 | 0.040 |
Why?
| | Communication | 1 | 2024 | 847 | 0.040 |
Why?
| | Delphi Technique | 1 | 2019 | 227 | 0.040 |
Why?
| | Epilepsy, Generalized | 1 | 2017 | 17 | 0.040 |
Why?
| | Ohio | 1 | 2017 | 152 | 0.030 |
Why?
| | Paraplegia | 1 | 2017 | 57 | 0.030 |
Why?
| | Insurance, Major Medical | 1 | 2017 | 2 | 0.030 |
Why?
| | Epilepsies, Partial | 1 | 2017 | 43 | 0.030 |
Why?
| | Microcephaly | 1 | 2018 | 87 | 0.030 |
Why?
| | Arkansas | 1 | 2016 | 15 | 0.030 |
Why?
| | Medical Records | 1 | 2017 | 171 | 0.030 |
Why?
| | Muscle Weakness | 1 | 2017 | 85 | 0.030 |
Why?
| | Serologic Tests | 1 | 2016 | 52 | 0.030 |
Why?
| | Serogroup | 1 | 2016 | 34 | 0.030 |
Why?
| | Headache | 1 | 2017 | 151 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2017 | 143 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2018 | 199 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 92 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 68 | 0.030 |
Why?
| | Self-Management | 1 | 2018 | 163 | 0.030 |
Why?
| | Spasms, Infantile | 1 | 2017 | 122 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1468 | 0.030 |
Why?
| | Geographic Mapping | 1 | 2015 | 21 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2016 | 130 | 0.030 |
Why?
| | Kansas | 1 | 2015 | 30 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 409 | 0.030 |
Why?
| | Forecasting | 1 | 2017 | 361 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1348 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 6423 | 0.030 |
Why?
| | Genome, Viral | 1 | 2015 | 128 | 0.030 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 114 | 0.030 |
Why?
| | Public Health | 1 | 2018 | 487 | 0.030 |
Why?
| | Coconut Oil | 1 | 2013 | 3 | 0.030 |
Why?
| | Nutrition Therapy | 1 | 2013 | 32 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 1020 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1269 | 0.020 |
Why?
| | RNA, Viral | 1 | 2015 | 620 | 0.020 |
Why?
| | Phylogeny | 1 | 2015 | 845 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 201 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 10241 | 0.020 |
Why?
| | Review Literature as Topic | 1 | 2008 | 66 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2511 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1708 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5437 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6550 | 0.020 |
Why?
| | Data Collection | 1 | 2008 | 653 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3971 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 9801 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1597 | 0.010 |
Why?
| | Biomedical Research | 1 | 2008 | 640 | 0.010 |
Why?
| | Research Design | 1 | 2008 | 1045 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 14553 | 0.010 |
Why?
|
|
Pastula's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|